Physician profile
Asha Dusad
NPI 1427498120
$842.53
in general payments reported to CMS, 2019-2025
12 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Child & Adolescent Psychiatry provider received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $220 · 2024: $266 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $843.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $842.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $201.78 | 2023-2025 | Wakix |
| Otsuka America Pharmaceutical, INC. | $187.18 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Abbvie INC. | $124.89 | 2023 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.73 | 2023-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $54.34 | 2024-2025 | Cobenfy |
| Vanda Pharmaceuticals INC. | $53.48 | 2024 | Hetlioz, Fanapt |
| Noven Therapeutics, LLC | $39.46 | 2024-2025 | Xelstrym, Secuado |
| Eisai INC. | $35.49 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $30.74 | 2023-2024 | Spravato |
| Collegium Pharmaceutical, INC. | $18.87 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $14.63 | 2024 | Quviviq |
| Ironshore Pharmaceuticals INC. | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asha Dusad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.